Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Public ClinicalTrials.gov record NCT04221945. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival. Once the study objectives have been met or the study has ended, participants will be discontinued from this study and will be enrolled in an extension study to continue protocol-defined assessments and treatment.
Study identification
- NCT ID
- NCT04221945
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,060 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Placebo for pembrolizumab Drug
- Cisplatin Drug
- External Beam Radiotherapy (EBRT) Radiation
- Brachytherapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 12, 2020 (Actual)
- Primary completion
- Jan 7, 2025 (Actual)
- Completion
- Jan 26, 2026 (Actual)
- Last update posted
- Feb 20, 2026
2020 – 2026
United States locations
- U.S. sites
- 28
- U.S. states
- 20
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute - Biltmore ( Site 8009) | Phoenix | Arizona | 85016 | — |
| UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) ( Site 0027) | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian ( Site 0038) | Newport Beach | California | 92663 | — |
| UC Davis Comprehensive Cancer Center ( Site 0017) | Sacramento | California | 95817 | — |
| University of Colorado Health Sciences Center and Hospital ( Site 0028) | Denver | Colorado | 80262 | — |
| Smilow Cancer Center at Yale-New Haven ( Site 0023) | New Haven | Connecticut | 06510 | — |
| AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 0009) | Orlando | Florida | 32804 | — |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0026) | Fort Wayne | Indiana | 46845 | — |
| University of Kentucky Markey Cancer Center ( Site 0015) | Lexington | Kentucky | 40536 | — |
| Our Lady of the Lake Regional Medical Center. ( Site 0031) | Baton Rouge | Louisiana | 70817 | — |
| Women's Cancer Care ( Site 0039) | Covington | Louisiana | 70433 | — |
| Karmanos Cancer Institute ( Site 0018) | Detroit | Michigan | 48201 | — |
| Minnesota Oncology Hematology, PA ( Site 8007) | Minneapolis | Minnesota | 55404 | — |
| University of New Mexico Comprehensive Cancer Center-Clinical Research Office ( Site 0019) | Albuquerque | New Mexico | 87106 | — |
| University of North Carolina at Chapel Hill ( Site 0025) | Chapel Hill | North Carolina | 27514 | — |
| Sanford Bismarck Medical Center ( Site 0046) | Bismarck | North Dakota | 58501 | — |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C | Columbus | Ohio | 43210 | — |
| Willamette Valley Cancer Institute and Research Center ( Site 8000) | Eugene | Oregon | 97401 | — |
| Legacy Good Samaritan Medical Center ( Site 0013) | Portland | Oregon | 97210 | — |
| Allegheny Health Network West Penn Hospital-Gynecologic Oncology ( Site 0030) | Pittsburgh | Pennsylvania | 15244 | — |
| Hollings Cancer Center ( Site 0007) | Charleston | South Carolina | 29425 | — |
| Sanford Gynecology Oncology ( Site 0003) | Sioux Falls | South Dakota | 57104 | — |
| Texas Oncology-Austin Central ( Site 8006) | Austin | Texas | 78731 | — |
| Texas Oncology-Fort Worth Cancer Center ( Site 8001) | Fort Worth | Texas | 76104 | — |
| Texas Oncology-San Antonio Medical Center ( Site 8002) | San Antonio | Texas | 78240 | — |
| Texas Oncology-The Woodlands ( Site 8003) | The Woodlands | Texas | 77380 | — |
| UVA Health System ( Site 0005) | Charlottesville | Virginia | 22908 | — |
| Virginia Commonwealth University ( Site 0024) | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 148 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04221945, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04221945 live on ClinicalTrials.gov.